Aviva PLC Incyte Corp Transaction History

Aviva PLC

$36.8 Billion
Q3 2024

A detailed history of Aviva PLC transactions in Incyte Corp stock. As of the latest transaction made, Aviva PLC holds 6,890 shares of INCY stock, worth $498,904. This represents 0.0% of its overall portfolio holdings.

Number of Shares

6,890

Previous 76,614 91.01%

Holding current value

$498,904

Previous $4.64 Million 90.2%

% of portfolio

0.0%

Previous 0.01%

30 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	SELL	$57.33 - $68.61 $4 Million - $4.78 Million	-69,724 Reduced 91.01%	6,890 $455,000
Q2 2024 Aug 02, 2024	SELL	$51.18 - $63.75 $2.96 Million - $3.68 Million	-57,773 Reduced 42.99%	76,614 $4.64 Million
Q1 2024 May 14, 2024	BUY	$56.55 - $66.59 $4.22 Million - $4.98 Million	74,712 Added 125.2%	134,387 $7.66 Million
Q4 2023 Feb 09, 2024	SELL	$52.16 - $64.19 $3.67 Million - $4.51 Million	-70,280 Reduced 54.08%	59,675 $3.75 Million
Q3 2023 Nov 13, 2023	SELL	$57.77 - $65.93 $1.82 Million - $2.08 Million	-31,588 Reduced 19.55%	129,955 $7.51 Million
Q2 2023 Aug 10, 2023	SELL	$60.95 - $75.51 $30.7 Million - $38 Million	-503,672 Reduced 75.72%	161,543 $10.1 Million
Q1 2023 May 12, 2023	BUY	$70.23 - $86.01 $19.5 Million - $23.9 Million	277,735 Added 71.68%	665,215 $48.1 Million
Q4 2022 Feb 09, 2023	SELL	$67.18 - $84.11 $228,882 - $286,562	-3,407 Reduced 0.87%	387,480 $31.1 Million
Q3 2022 Nov 14, 2022	BUY	$66.18 - $82.86 $3.91 Million - $4.89 Million	59,056 Added 17.8%	390,887 $26 Million
Q2 2022 Aug 04, 2022	BUY	$66.18 - $83.18 $15.1 Million - $18.9 Million	227,766 Added 218.87%	331,831 $25.2 Million
Q1 2022 May 13, 2022	BUY	$66.02 - $79.71 $1.55 Million - $1.87 Million	23,430 Added 29.06%	104,065 $8.27 Million
Q4 2021 Feb 10, 2022	BUY	$63.34 - $74.11 $1.53 Million - $1.79 Million	24,141 Added 42.73%	80,635 $5.92 Million
Q3 2021 Nov 12, 2021	SELL	$68.67 - $84.02 $207,177 - $253,488	-3,017 Reduced 5.07%	56,494 $3.89 Million
Q2 2021 Aug 10, 2021	SELL	$79.87 - $87.53 $1.31 Million - $1.44 Million	-16,411 Reduced 21.62%	59,511 $5.01 Million
Q1 2021 May 13, 2021	BUY	$76.02 - $100.5 $96,241 - $127,233	1,266 Added 1.7%	75,922 $6.17 Million
Q4 2020 Feb 10, 2021	SELL	$80.74 - $97.7 $840,422 - $1.02 Million	-10,409 Reduced 12.24%	74,656 $6.49 Million
Q3 2020 Nov 12, 2020	BUY	$85.07 - $109.69 $201,700 - $260,074	2,371 Added 2.87%	85,065 $7.63 Million
Q2 2020 Aug 13, 2020	SELL	$74.18 - $108.93 $2.4 Million - $3.53 Million	-32,416 Reduced 28.16%	82,694 $8.6 Million
Q1 2020 May 14, 2020	BUY	$63.18 - $85.97 $2.01 Million - $2.73 Million	31,784 Added 38.14%	115,110 $8.43 Million
Q4 2019 Feb 10, 2020	BUY	$73.04 - $95.72 $1.52 Million - $1.99 Million	20,777 Added 33.22%	83,326 $7.28 Million
Q3 2019 Nov 12, 2019	SELL	$72.82 - $86.52 $165,665 - $196,833	-2,275 Reduced 3.51%	62,549 $4.64 Million
Q2 2019 Jul 30, 2019	SELL	$73.52 - $88.7 $106,456 - $128,437	-1,448 Reduced 2.18%	64,824 $5.51 Million
Q1 2019 May 14, 2019	BUY	$63.56 - $88.17 $31,970 - $44,349	503 Added 0.76%	66,272 $5.7 Million
Q4 2018 Feb 12, 2019	SELL	$58.5 - $69.94 $1.11 Million - $1.33 Million	-19,003 Reduced 22.42%	65,769 $4.18 Million
Q3 2018 Nov 13, 2018	SELL	$61.75 - $74.23 $162,773 - $195,670	-2,636 Reduced 3.02%	84,772 $5.86 Million
Q2 2018 Aug 01, 2018	SELL	$60.85 - $83.98 $86,224 - $118,999	-1,417 Reduced 1.6%	87,408 $5.86 Million
Q1 2018 May 14, 2018	SELL	$83.06 - $100.98 $651,771 - $792,390	-7,847 Reduced 8.12%	88,825 $7.4 Million
Q4 2017 Feb 13, 2018	SELL	$93.56 - $116.6 $940,184 - $1.17 Million	-10,049 Reduced 9.42%	96,672 $9.16 Million
Q3 2017 Nov 13, 2017	BUY	$109.15 - $138.27 $160,450 - $203,256	1,470 Added 1.4%	106,721 $12.5 Million
Q2 2017 Aug 07, 2017	BUY	N/A	105,251	105,251 $13.3 Million

Others Institutions Holding INCY

# of Institutions

651

Shares Held

186M

Call Options Held

714K

Put Options Held

557K

View Full List

About INCYTE CORP

Ticker INCY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 222,431,008
Market Cap $16.1B
Description
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as ...

More about INCY

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Aviva PLC, based on Form 13F filings with the SEC.

News

Stay updated on Aviva PLC with notifications on news.

Account